Ipca Laboratories Ltd
Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)
- Market Cap ₹ 32,850 Cr.
- Current Price ₹ 1,295
- High / Low ₹ 1,758 / 1,168
- Stock P/E 36.7
- Book Value ₹ 274
- Dividend Yield 0.31 %
- ROCE 14.7 %
- ROE 12.8 %
- Face Value ₹ 1.00
Pros
- Company has been maintaining a healthy dividend payout of 17.9%
Cons
- Stock is trading at 4.73 times its book value
- Company has a low return on equity of 10.3% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3,282 | 3,144 | 2,867 | 3,156 | 3,258 | 3,746 | 4,619 | 5,395 | 5,797 | 6,204 | 7,662 | 8,897 | 9,156 | |
| 2,539 | 2,604 | 2,573 | 2,705 | 2,803 | 3,051 | 3,715 | 3,843 | 4,472 | 5,272 | 6,338 | 7,166 | 7,406 | |
| Operating Profit | 743 | 541 | 294 | 451 | 455 | 695 | 904 | 1,552 | 1,325 | 932 | 1,324 | 1,731 | 1,750 |
| OPM % | 23% | 17% | 10% | 14% | 14% | 19% | 20% | 29% | 23% | 15% | 17% | 19% | 19% |
| 21 | 32 | 21 | 11 | 41 | 56 | 65 | 59 | 54 | 123 | 17 | -114 | -100 | |
| Interest | 30 | 32 | 35 | 27 | 28 | 22 | 20 | 12 | 11 | 48 | 141 | 88 | 79 |
| Depreciation | 103 | 180 | 163 | 173 | 178 | 182 | 210 | 209 | 232 | 262 | 357 | 398 | 399 |
| Profit before tax | 631 | 361 | 117 | 262 | 291 | 546 | 739 | 1,389 | 1,136 | 745 | 843 | 1,131 | 1,171 |
| Tax % | 24% | 28% | 18% | 26% | 18% | 19% | 18% | 17% | 20% | 34% | 37% | 30% | |
| 479 | 254 | 93 | 195 | 239 | 442 | 604 | 1,141 | 890 | 479 | 523 | 785 | 819 | |
| EPS in Rs | 18.96 | 10.07 | 3.69 | 7.71 | 9.49 | 17.60 | 23.99 | 44.94 | 34.85 | 18.58 | 21.57 | 29.08 | 30.69 |
| Dividend Payout % | 13% | 5% | 0% | 6% | 5% | 9% | 10% | 9% | 11% | 22% | 19% | 14% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 15% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 7% |
| 3 Years: | -1% |
| TTM: | 44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 2% |
| 3 Years: | 13% |
| 1 Year: | -19% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 14% |
| 3 Years: | 10% |
| Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| Reserves | 1,934 | 2,183 | 2,234 | 2,430 | 2,663 | 3,097 | 3,602 | 4,676 | 5,439 | 5,817 | 6,307 | 6,923 |
| 603 | 935 | 867 | 716 | 628 | 465 | 501 | 265 | 807 | 1,481 | 1,438 | 1,363 | |
| 648 | 669 | 765 | 788 | 799 | 961 | 1,130 | 1,099 | 1,349 | 1,300 | 3,326 | 3,432 | |
| Total Liabilities | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,622 | 8,623 | 11,097 | 11,744 |
| 1,354 | 1,800 | 2,014 | 1,983 | 1,953 | 1,940 | 2,059 | 2,072 | 2,402 | 2,751 | 4,554 | 4,267 | |
| CWIP | 165 | 267 | 129 | 95 | 73 | 66 | 133 | 235 | 306 | 140 | 343 | 622 |
| Investments | 9 | 16 | 26 | 136 | 87 | 120 | 310 | 505 | 989 | 626 | 862 | 980 |
| 1,683 | 1,729 | 1,723 | 1,746 | 2,003 | 2,422 | 2,756 | 3,254 | 3,924 | 5,105 | 5,339 | 5,875 | |
| Total Assets | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,622 | 8,623 | 11,097 | 11,744 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 522 | 468 | 709 | 282 | 341 | 501 | 570 | 1,090 | 856 | 806 | 945 | 1,321 | |
| -369 | -689 | -218 | -149 | -135 | -165 | -509 | -521 | -851 | -725 | -1,215 | -870 | |
| -136 | 251 | -462 | -159 | -130 | -183 | -137 | -306 | 427 | 507 | -553 | -283 | |
| Net Cash Flow | 18 | 29 | 29 | -26 | 75 | 153 | -76 | 264 | 432 | 588 | -823 | 169 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 50 | 41 | 57 | 58 | 67 | 66 | 71 | 55 | 57 | 58 | 80 | 77 |
| Inventory Days | 272 | 293 | 289 | 290 | 286 | 316 | 294 | 337 | 337 | 276 | 350 | 336 |
| Days Payable | 110 | 97 | 145 | 130 | 137 | 154 | 135 | 140 | 101 | 83 | 110 | 111 |
| Cash Conversion Cycle | 213 | 237 | 200 | 218 | 216 | 228 | 229 | 251 | 293 | 251 | 321 | 302 |
| Working Capital Days | 82 | 68 | 61 | 74 | 80 | 88 | 88 | 103 | 102 | 71 | 111 | 101 |
| ROCE % | 28% | 14% | 5% | 9% | 10% | 16% | 19% | 31% | 20% | 11% | 13% | 15% |
Documents
Announcements
-
Board Meeting Outcome for Outcome Of Board Meeting
17 Oct - Ipca to slump-sell Ankleshwar API/intermediates unit to Suleshvari Pharma for Rs.22.15 crore; completion by 31 Dec 2025.
-
Slump Sale Of Company''s Apis And Drug Intermediates Manufacturing Unit Situated At Ankleshwar
17 Oct - Slump sale of Ankleshwar API unit to Suleshvari Pharma for Rs.22.15 crore; completion by Dec 31, 2025.
-
Slump Sale Of Company''s Apis And Drug Intermediates Manufacturing Unit Situated At Ankleshwar
17 Oct - Board approved slump sale of Ankleshwar API unit to Suleshvari for Rs.22.15 crore; completion by Dec 31, 2025.
-
Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For The 2Nd Quarter And Half Year Ended 30.09.2025
17 Oct - Board meeting 13 Nov 2025 to consider Q2/H1 unaudited results; trading window closed till 15 Nov.
-
Incorporation Of A Wholly Owned Subsidiary In Germany
16 Oct - Incorporated wholly-owned Ipca Pharmaceuticals GmbH (Germany) with €25,000 capital for registrations and generic distribution.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from web
-
Financial Year 2024
from bse
-
Financial Year 2023
from web
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
Concalls
-
Aug 2025TranscriptPPT
-
Jun 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024TranscriptPPT
-
Jun 2024TranscriptPPT
-
Feb 2024TranscriptPPT
-
Nov 2023TranscriptPPT
-
Aug 2023TranscriptPPT
-
Apr 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Mar 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
Jun 2020TranscriptPPT
-
Feb 2020TranscriptPPT
-
Nov 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Nov 2018TranscriptPPT
Integrated nature of operations
Ipca Laboratories is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. [1]
IPCA is among India’s top 20 pharmaceutical companies. [2]
Business segments FY22:
API Business (25%) [3]
Ipca produces over 80 APIs, nearly 79% of the APIs and Intermediates business is from exports making them one of India’s top exporters of APIs, serving over 100 countries around the globe. The core strategic focus has been on backward integration, resulting in superior supply chain reliability and cost competitiveness [4] [1] [5]